BioAegis Therapeutics

09/01/2021

September is Sepsis Awareness Month.

BioAegis co-founder, Steven Cordovano shares why Wallstreet's funding of sepsis treatment has dwindled and how the US Government is now stepping in with a renewed focus on this very serious disease. More than 1.7 million people in the US develop sepsis each year.

We were recently awarded a contract with Biomedical Advanced Research and Development Authority to advance our -directed inflammation regulator for severely ill patients with and .



National Institutes of Health (NIH) Valerie Ceva Susan L. Levinson

As Wallstreet Funding for Sepsis Research has Evaporated US Government Funding Picks Up the Slack

03/25/2021

Insightful article written by our CEO, Dr. Susan Levinson.

Susan shares her views on why the US should focus on conquering Covid’s main culprit— —to prevent people from becoming seriously ill and dying. This is the very same inflammation that is the cause of a wide range of chronic diseases -- and a likely culprit in people who suffer long-term symptoms after surviving their acute infection.

The US is overlooking Covid’s main culprit — and the threat that vaccines do not address.

12/17/2020

therapy as a treatment for acute respiratory distress syndrome, , is included in Research and Markets' market forecast.

/PRNewswire/ -- The "Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast - 2030" report has been added to...

11/16/2020

Expanding the footprint of the of our inflammation regulator, , for the treatment of .

This study assesses recombinant human plasma gelsolin (rhu-pGSN), and its unique ability to regulate the overactive inflammatory response often responsible for causing and death in COVID-19 patients.

Rhu-pGSN does not compromise the immune response as compared to other immune suppressive anti-inflammatory agents (e.g. ).

Low levels of this human plasma protein are associated with severe illness, organ failure and mortality in COVID-19 patients.

No drug-related safety signals identified by the independent Data and Safety Monitoring Board.MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) --...

09/30/2020

Thrilled that our CEO, Dr. Susan Levinson, will also be presenting.

Special Keynote: An Update on Johnson & Johnson's Leading COVID-19 Vaccine Candidate

Register today & start connecting with hundreds of life sciences professionals: https://conta.cc/3icbMmQ

09/15/2020

Another community acquired market report that recognizes as a key player.

The Community Acquired Pneumonia Drugs Market document makes businesses powerful whether it is large medium or small for existing and succeeding in the market The report holds a massive importance when it comes to market definition classifications applications and engagements ...

09/08/2020

“The compelling data from this NIH sponsored study show the potential of to not only improve survival, but to diminish lung injury caused by virulent . Having shown animal efficacy in multidrug resistant gram positive and negative pneumonia, as well as severe flu, we look forward to results of our ongoing clinical study in severe patients." Susan Levinson, PhD, CEO of BioAegis

MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious,...

08/19/2020

BioAegis Conducting COVID-19 Clinical Trial of Gelsolin Therapeutic MORRISTOWN, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing…

08/18/2020

There is still time to register and hear our incredible female
co-founders and leaders Valerie Ceva and Susan Levinson.

The leadership team of BioAegis Therapeutics will share their experiences as they reframed their strategy to address the COVID-19 threat to their employees and hustled to initiate a clinical trial for severe COVID-19 patients.

Learn more and register: https://www.womeninbio.org/events/EventDetails.aspx?id=1411754&group=

Thank you to Skadden, Arps, Slate, Meagher & Flom LLP, LifeSci Advisors, Thompson Hine LLP, and Wiggin And Dana LLP for sponsoring this event!

08/06/2020

First patient enrolled in our Phase 2 Clinical Trial of recombinant human plasma gelsolin (rhu-pGSN).

Thank you Dr. Sandra Parra and her team at Hospital Universitari Sant Joan de Reus in Tarragona, Spain

08/06/2020

Phase 2 Trial of for treatment BEGINS!

Gelsolin, a key component of the body's system and a 'master regulator of ' has the potential to disrupt the course of the created by COVID-19.

"We are excited to move forward with this study to address the most severe outcomes of COVID-19. Two recent independent publications confirm that COVID 19 patients with lower gelsolin levels are more likely to exhibit organ damage and have higher WHO scores. Now, we have the opportunity to prevent these poor outcomes in patients in Spain." Susan Levinson, PhD, CEO of BioAegis

MORRISTOWN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious,...

07/24/2020

New Jersey-based BioAegis Therapeutics Inc., has received regulatory clearance for its Phase 2 Proof of Concept study of its COVID-19 treatment.